Hepatology highlights
Jean‐François Dufour – 22 February 2016
MAF1 suppresses AKT‐mTOR signaling and liver cancer through activation of PTEN transcription
Yue Li, Chi Kwan Tsang, Suihai Wang, Xiao‐Xing Li, Yang Yang, Liwu Fu, Wenlin Huang, Ming Li, Hui‐Yun Wang, X.F. Steven Zheng – 22 February 2016 – The phosphatidylinositol 3‐kinase/phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase/protein kinase B/mammalian target of rapamycin (PI3K‐PTEN‐AKT‐mTOR) pathway is a central controller of cell growth and a key driver for human cancer. MAF1 is an mTOR downstream effector and transcriptional repressor of ribosomal and transfer RNA genes.
Masthead
22 February 2016
Incidence of hepatocellular carcinoma after seroclearance is not reduced
Chee‐Kiat Tan – 18 February 2016
Beta‐blockers in 2016: Still the safest and most useful drugs for portal hypertension?
Gennaro D'Amico, Giuseppe Malizia, Jaime Bosch – 18 February 2016
Reply
Jospehine Simonetti, Lisa Bulkow, Brian J. McMahon, Chriss Homan, Mary Snowball, Susan Negus, James Williams, Stephen E. Livingston – 18 February 2016
Nonalcoholic fatty liver disease and elastography: Incremental advances but work still to be done
William N. Hannah, Stephen A. Harrison – 18 February 2016
The many faces of positive hepatitis B surface antigen
Derek M. Tang, Theo Heller, Christopher Koh – 18 February 2016
Atorvastatin and fluvastatin are associated with dose‐dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES
Tracey G. Simon, Hector Bonilla, Peng Yan, Raymond T. Chung, Adeel A. Butt – 18 February 2016 – Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV.